Aligos Therapeutics Inc is a biotechnology business based in the US. Aligos Therapeutics shares (ALGS) are listed on the NASDAQ and all prices are listed in US Dollars. Aligos Therapeutics employs 86 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Aligos Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ALGS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Aligos Therapeutics stock price (NASDAQ: ALGS)Use our graph to track the performance of ALGS stocks over time.
Aligos Therapeutics shares at a glance
|Latest market close||$15.72|
|52-week range||$13.30 - $37.51|
|50-day moving average||$15.47|
|200-day moving average||$19.97|
|Wall St. target price||$34.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.57|
Buy Aligos Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Aligos Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aligos Therapeutics price performance over time
|1 week (2021-10-18)||-0.13%|
|1 month (2021-09-24)||15.72|
|3 months (2021-07-23)||-5.02%|
|6 months (2021-04-23)||-35.76%|
|1 year (2020-10-23)||4.11%|
|2 years (2019-10-21)||N/A|
|3 years (2018-10-21)||N/A|
|5 years (2016-10-21)||N/A|
Aligos Therapeutics financials
|Revenue TTM||$2.5 million|
|Gross profit TTM||$0|
|Return on assets TTM||-44.26%|
|Return on equity TTM||-101.43%|
|Market capitalisation||$669.8 million|
TTM: trailing 12 months
Shorting Aligos Therapeutics shares
There are currently 1.9 million Aligos Therapeutics shares held short by investors – that's known as Aligos Therapeutics's "short interest". This figure is 9.5% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Aligos Therapeutics shares can be evaluated.
Aligos Therapeutics's "short interest ratio" (SIR)
Aligos Therapeutics's "short interest ratio" (SIR) is the quantity of Aligos Therapeutics shares currently shorted divided by the average quantity of Aligos Therapeutics shares traded daily (recently around 301243.42313788). Aligos Therapeutics's SIR currently stands at 6.31. In other words for every 100,000 Aligos Therapeutics shares traded daily on the market, roughly 6310 shares are currently held short.
To gain some more context, you can compare Aligos Therapeutics's short interest ratio against those of similar companies.
However Aligos Therapeutics's short interest can also be evaluated against the total number of Aligos Therapeutics shares, or, against the total number of tradable Aligos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aligos Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aligos Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0994% of the tradable shares (for every 100,000 tradable Aligos Therapeutics shares, roughly 99 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aligos Therapeutics.
Find out more about how you can short Aligos Therapeutics stock.
Aligos Therapeutics share dividends
We're not expecting Aligos Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
- Gilead Sciences (GILD.US) (4.15% forward annual dividend yield)
Aligos Therapeutics overview
Aligos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co. , Ltd.
Aligos Therapeutics in the news
Investors in Aligos Therapeutics (NASDAQ:ALGS) have made a return of 17% over the past year
We're Not Very Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD’S The Liver Meeting® 2021
Frequently asked questionsWhat percentage of Aligos Therapeutics is owned by insiders or institutions?
Currently 16.779% of Aligos Therapeutics shares are held by insiders and 75.547% by institutions. How many people work for Aligos Therapeutics?
Latest data suggests 86 work at Aligos Therapeutics. When does the fiscal year end for Aligos Therapeutics?
Aligos Therapeutics's fiscal year ends in December. Where is Aligos Therapeutics based?
Aligos Therapeutics's address is: One Corporate Drive, South San Francisco, CA, United States, 94080 What is Aligos Therapeutics's ISIN number?
Aligos Therapeutics's international securities identification number is: US01626L1052
More guides on Finder
How to buy ProShares Bitcoin Strategy ETF (BITO)
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
How to buy Vaxxinity (VAXX) stock when it goes public
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
How to buy Entrada Therapeutics (TRDA) stock when it goes public
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Ask an Expert